Disclosed positions

Estimated from their latest filings — positions may have changed since

$5.42M

combined est. value

Stock	Shares	Price	Value	Weight	As of
GRALGRAIL, Inc.	42,702	$70.14	$3.00M	55%	2026-06-18
NTLAIntellia Therapeutics, Inc.	143,893	$16.84	$2.42M	45%	2026-06-09

GRAL

GRAIL, Inc.

$3.00M

42,702 sh

NTLA

Intellia Therapeutics, Inc.

$2.42M

143,893 sh

Activity

Open-market buy & sell volume

BuySell

Total +$1.00M bought

Most bought

NTLA

$1.00M

All filings on record

Every Form 4 transaction we track for this filer

all 8buys 1sells 0

Stock	Transaction	Date	~6mo later
GRALGRAIL, Inc.	Grant $350.0K · 5,491 sh	2026-06-18	—
NTLAIntellia Therapeutics, Inc.	Grant — · 9,200 sh	2026-06-09	—
GRALGRAIL, Inc.	Grant $20.8K · 213 sh	2026-01-15	—
GRALGRAIL, Inc.	Grant $20.8K · 275 sh	2025-10-15	—
NTLAIntellia Therapeutics, Inc.	Buy $1.00M · 100,000 sh	2025-08-20	+17.5%
GRALGRAIL, Inc.	Grant $20.5K · 533 sh	2025-07-15	—
NTLAIntellia Therapeutics, Inc.	Grant — · 8,000 sh	2025-06-11	—
GRALGRAIL, Inc.	Grant $250.0K · 6,082 sh	2025-05-29	—

GRALGrant

2026-06-18 · GRAIL, Inc.

$350.0K

—

NTLAGrant

2026-06-09 · Intellia Therapeutics, Inc.

9,200

—

GRALGrant

2026-01-15 · GRAIL, Inc.

$20.8K

—

GRALGrant

2025-10-15 · GRAIL, Inc.

$20.8K

—

NTLABuy

2025-08-20 · Intellia Therapeutics, Inc.

$1.00M

+17.5%

GRALGrant

2025-07-15 · GRAIL, Inc.

$20.5K

—

NTLAGrant

2025-06-11 · Intellia Therapeutics, Inc.

8,000

—

GRALGrant

2025-05-29 · GRAIL, Inc.

$250.0K

—

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.